pSivida Corp and Alimera Sciences Inc said they would try a fourth time to get approval for an eye treatment for diabetes patients, sending the shares of both companies soaring. Alimera Sciences shares jumped 88 percent and pSivida stock climbed 62 percent in premarket trade. The drug-device combination, Iluvien, is a sustained-release eye implant used to treat vision loss associated with chronic diabetic macular edema (DME).
Help employers find you! Check out all the jobs and post your resume.
